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ABSTRACT  
COPD is one of the leading causes of mortality and morbidity worldwide. One of the 
most important features of this disease is exacerbations where a patient’s respiratory 
symptoms episodically worsen. Exacerbations accounted for over 140,000 hospital 
admissions in 2012 in the UK with considerably more exacerbations being treated in 
primary care. Despite significant research in this area in recent years, treatment of acute 
exacerbations in the community remains limited to oral glucocorticoids, antibiotics and 
bronchodilators. One of the issues with unpicking the complexity of exacerbations is 
trying to find out the exact underlying cause and mechanism that leads to symptoms 
and lung destruction. Currently symptoms are initially guided by symptoms alone 
though multiple causes of exacerbations have common presentations. This includes 
viral and bacterial infections and episodes relating to environmental triggers such as 
pollen and pollution. There is also evidence that cardiovascular factors can contribute to 
symptoms of breathlessness that can mimic COPD exacerbations. In this editorial we 
discuss recent advances in the use of precision medicine to more accurately treat 
exacerbations of COPD. This includes identification of phenotypes that could help 
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rationalise treatment and more importantly identify novel drug targets. We also 
consider the future role of precision medicine in preventing exacerbations and 
identifying COPD patients that are at increased risk of developing them. This includes 
use of clinical features, biomarker data and genetic indicators of future exacerbations.  
Core tip: COPD patients and the exacerbations they suffer are complex and 
heterogenous in nature. They should all be treated on an individual basis with detailed 
clinical history and initial work up to better understand the impact it is having on their 
life. Careful consideration of the benefits of treatment should be weighed up against the 
risks of their side effects to ensure the maximum benefit of treatment. Precision 
medicine is starting to appear in management of COPD, both for acute exacerbations 
and their prevention. 
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INTRODUCTION 
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable chronic lung 
condition that is projected to be the 3rd leading cause of death globally by 2030. It is a diverse 
disease with a wide variation in symptoms and severity and associated comorbidities including 
osteoporosis(1) and sarcopenia(2). One of the most important features of COPD are episodes of 
acute worsening of respiratory symptoms, more commonly known as exacerbations. Such 
episodes often require additional therapy in an attempt to reduce their impact, duration and 
limit damage to the lungs. COPD exacerbations are associated with increased mortality(3), 
worse qualify of life(4) and more rapid lung function decline.  
There has been little change to the repertoire of therapies available to AECOPD in the last 30 
years(5). The main stay of treatment remains oral glucocorticoids and inhaled bronchodilators 
plus antibiotics if a bacterial infection is suspected(6). Treatment of COPD exacerbations in the 
community is mainly based on symptoms alone. Since the symptoms of COPD exacerbations 
are the result of numerous possible aetiologies (infection, environmental, psychological, 
cardiovascular) with little in the way of features that can predict the exact cause, most are 
treated with a “one size fits all” approach. 
COPD patients also suffer with marked variation in day to day symptoms including 
breathlessness, sputum production, sputum colour, fatigue and levels of stress and anxiety. This 
presents a challenge for physicians to accurately treat exacerbations. How can a distinction be 
made between the usual daily variation in symptoms and an emerging exacerbation?  
It is clear that more sophisticated and personalised approaches are required to improve 
accuracy of treating COPD exacerbations and crucially early identification of moderate or 
severe exacerbations to enable prompt treatment. Precision medicine has been defined as 
“treatments targeted to the needs of individual patients on the basis of genetic, biomarker, 
phenotypic, or psychosocial characteristics that distinguish a given patient from other patients 
with similar clinical presentations(7)”. The ultimate aim of personalised medicine is to improve 
clinical outcomes for patients whilst avoiding side effects for those who are unlikely to benefit 
from therapy(7). In the context of treating COPD exacerbations this means diagnosing and 
treating patients based on factors that separate exacerbations into unique phenotypes. This is 
likely to include measurement of biological samples (blood, urine or sputum) during the early 
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phase of an exacerbation and potentially by monitoring them at regular intervals to detect when 
an exacerbation is developing. Such advanced near patient testing is on the horizon with the 
development of more reliable and cost-effective methods of measuring patient biomarkers in a 
primary care setting(8). 
Precision medicine for COPD exacerbations could also mean identifying those at an increased 
risk of future exacerbations and tailoring treatment to individuals to reduce the rate and impact 
of them on the patient. This again is likely to involve cross sectional biomarker measurement or 
even genetic analysis. 
PERSONALISED APPROACHES TO TREATMENT OF 
ACUTE EXACERBATIONS  
Exacerbations have numerous causes, often with similar presentations, namely breathlessness 
and sputum production. Similar symptoms do not infer similar underlying pathophysiology. 
For example, a bacterial exacerbation may respond well to antibiotics but may be worsened by 
the use of steroids due to immunosuppression. Equally, exacerbations with an allergic or 
environmental trigger may have little or no response to antibiotics and expose the patient to 
side effects and potential antibiotic resistance needlessly. It is also difficult to be sure which 
types of exacerbations lead to lung destruction (if at all). Causes of exacerbations that mimic 
symptoms of ‘true’ AECOPD, such as those triggered by cardiogenic factors by stress or 
anxiety, may not be associated with underlying damage to lung tissue or disease progression. 
Discovery of exacerbation phenotypes; traits that are observed clinically or functionally, or even 
endotypes; cellular and molecular pathways involved in the pathogenesis of the disease, would 
enable more personalised treatment of acute episodes(9). This is likely to include use of 
symptoms, physiological measurements or biomarkers to stratify exacerbations.  
The acute phase protein C reactive protein (CRP) is a widely used clinical biomarker of 
inflammation and infection (10) and several studies have looked at its usefulness as a biomarker 
to select patients who would benefit from antibiotics during COPD exacerbations(8) (11). Most 
studied hospitalised patients and though use of CRP to guide treatment was non-inferior and 
led to a reduction in antibiotic use it did not lead to any improvement in other outcomes. Only 
the PACE study (8) has carried out an RCT of COPD patients in a primary care setting and 
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results of other studies may not be generalisable to the majority of COPD exacerbations that are 
treated in the community.  
Procalcitonin has also been touted as a potential biomarker though currently its expense and 
lack of availability in routine clinical care make it less attractive(12).  
As with predicting future risk using eosinophils, acute treatment of exacerbations with oral 
glucocorticoids in those patients with higher eosinophil counts was found to be non-inferior to 
standard treatment in hospitalised patients(13) and further adds merit to the theory of the 
eosinophilic exacerbation phenotype.   
Despite their promise, use of CRP and procalcitonin to guide antibiotic treatment and 
eosinophils to guide use of oral glucocorticoids may be seen as a backward step. Instead of 
pioneering new treatments for exacerbations it is merely rationalising old ones. To truly move 
forward into the age of precision medicine we must identify specific exacerbation endotypes 
with the hope of identifying novel drug targets. In order to achieve this, we must deepen our 
understanding of the pathophysiological process’s involved in the early and established stages 
of the exacerbation period. 
An alternative to measuring direct markers of inflammation is to identify biomarkers that 
represent organ or tissue damage. One well established example is troponin which has 
revolutionised triage of patients with myocardial infarction(14). It has been proposed that 
COPD exacerbations should be considered “lung attacks” with each episode furthering damage 
to the lungs with consequences for future morbidity and mortality(15). Markers of elastin 
degradation have been proposed as the lung equivalent biomarker of lung tissue destruction 
since loss of alveolar elastic tissue within the lungs is the main contributor to pulmonary 
emphysema, a process driven by an imbalance of proteases and anti-proteases(16). This has led 
to particular interest into elastin degradation products as biomarkers of emphysema 
progression(17) and pulmonary exacerbations of COPD(18) though it has proved difficult to 
validate clinically(19, 20). Elastin is also found in blood vessels(21) and therefore ‘non-lung’ 
elastin may introduce additional noise to the data. Furthermore, in advanced pulmonary 
emphysema the baseline desmosine level may be lower since there is less lung tissue left to be 
broken down, independent of disease activity(22), making direct comparisons difficult. 
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An emerging area of study is the role of the lung microbiome and its influence on 
exacerbations(23). Advances in DNA sequencing in recent years has allowed for sophisticated 
profiling of the lung microbiome, something that traditional cell culture could not achieve 
consistently. The interplay between the host immune system and lung microbiota are complex 
but studies have shown the relative abundance and variety of bacteria within the respiratory 
tract is dynamic between stable state and exacerbations(24). This may provide new opportunity 
for identifying biomarkers of exacerbations and crucially new therapies(25).    
PREDICTING FUTURE EXACERBATIONS OF COPD 
Assessing individual risk of having pulmonary exacerbations forms a key part in choosing 
initial and subsequent therapy. Stratifying COPD exacerbation risk continues to be a challenge, 
particularly when a COPD patient is first diagnosed. Analysis of data from the SPIROMICS 
cohort in 2017 found marked variation in annual frequency of moderate to severe exacerbations 
requiring hospitalisation(26). 
Spirometry is a useful tool to assess COPD severity, and those with an FEV1 <50% predicted are 
at higher risk of suffering with exacerbations. Although GOLD severity level correlates with 
risk of COPD exacerbations, FEV1 alone varies too widely to be a reliable predictor. It is, 
however, useful in conjunction with other patient factors(3). Deteriorating airflow obstruction is 
associated with increasing prevalence of exacerbations and hospitalisations(27). An important 
predictor of future exacerbations is a previous history of pulmonary exacerbations(28) and 
should be asked about in all patients with COPD. 
In recent years there has been research interest in the role of eosinophils in precision prevention 
of exacerbations of COPD. A recent systematic review (29) examined the results of 11 post-hoc 
analyses of RCTs (n = 25,881) and 5 retrospective observational studies (n = 109,704) of the effect 
of ICS on COPD exacerbation rate. They found a treatment effect at both a cut off of ≥2% (RR, 
0.80, 95% CI, 0.74 – 0.85) and ≥150 cells/µL blood eosinophil count (RR, 0.65, 0.52 – 0.79), 
though there was no observed effect in 4 of the 5 observational studies. The most recent GOLD 
guidelines have since incorporated eosinophil count to be considered as a factor for starting an 
ICS in those with a higher eosinophil count in combination with clinical assessment of 
exacerbation risk(6). Blood eosinophils are a good example of precision medicine in action 
today and its use as a biomarker for future exacerbations may mean that patients with a low 
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eosinophil count will avoid unnecessary side effects such as osteoporosis (30) who would have 
ordinarily received an ICS as part of routine care.  
There are other factors that may influence a decision to use ICS in patients with COPD. In those 
with a previous history of asthma or significant bronchodilator reversibility it may be beneficial 
to add in ICS therapy. Risk of pneumonia should always be thought about too, especially in the 
elderly, those with a low BMI and patients with bronchiectasis(31). These may be considered 
‘treatable traits’ and may be a flexible alternative to splitting COPD patients into rigid 
phenotypes(9).   
High eosinophils are also an example of a COPD phenotype in which a patient characteristic is 
associated with a clinically meaningful outcome, namely exacerbations. The underlying 
mechanism for eosinophilic exacerbations remains poorly understood but clinical trials that 
target inflammatory pathways that involve eosinophils have show promise(32, 33).  
Other biomarkers of exacerbation risk have been explored via large cohort studies but have 
been unsuccessful so far. Comparison of SPIROMICS and COPDgene data (n = 2146 patients in 
total) showed no biomarker candidates that can predict retrospective self-reported 
exacerbations or prospective exacerbations as defined by health care use(34).  
FUTURE DIRECTIONS 
Early changes in the inflammatory profile of an exacerbation may be key to understanding the 
downstream effects. It is well known that several inflammatory cells have similar end points in 
activating the immune system(5). If these early changes could be found then it may shed more 
light on the cause of an exacerbation. This is not easily done in a hospital setting but could be 
achieved in clinical trials with the use of home biomarker monitoring paired with symptom 
diaries. This would capture subclinical episodes and daily fluctuations that would otherwise be 
missed when using the healthcare utilisation criteria for exacerbations. It must be noted that 
even if a suitable biomarker is found, acceptable and applicable methods would need to be 
available and cost effective in order to make it clinically useful.  
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CONCLUSION 
Currently limited therapies are available for the treatment and prevention of COPD 
exacerbations beyond antibiotics, oral and inhaled steroids and bronchodilators(35). This is in 
part due to challenges in identifying clinically meaningful endotypes for COPD and stunted 
development of targeted therapies. Studies have also often excluded certain subgroups of 
COPD, such as those with other comorbidities, and subsequent poor identification of COPD 
endo/phenotypes. There have, however, been promising results from studies in eosinophilic 
COPD with further phenotypes emerging from more recent studies. In combination with 
advancements in near patient testing technologies there is hope for more precise treatment of 
COPD exacerbations in the near future.   
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